WO2005070437A1 - 疼痛の治療のための医薬 - Google Patents
疼痛の治療のための医薬 Download PDFInfo
- Publication number
- WO2005070437A1 WO2005070437A1 PCT/JP2005/000979 JP2005000979W WO2005070437A1 WO 2005070437 A1 WO2005070437 A1 WO 2005070437A1 JP 2005000979 W JP2005000979 W JP 2005000979W WO 2005070437 A1 WO2005070437 A1 WO 2005070437A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pain
- rbl
- ginsenoside
- medicament
- weeks
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a medicament for treating and / or preventing pain such as neuropathic pain that occurs after peripheral nerve injury or central nerve injury.
- Peripheral neuropathy causes hypoesthesia and decreased motor function, while hyperalgesia (increased responsiveness to stimuli that are usually painful) perodiure (pain caused by stimuli that usually do not cause pain), etc.
- causes neuropathic pain sometimes called “neuropathic pain” or “neuropathic pain”).
- Neuropathic pain is the most aggressive effect of afferent primary sensory neurons when the primary sensory neuron is injured for any reason. The mechanism of onset is still unknown and no effective treatment has been established. Painful pain (Textbook of Pain, 3rd Edition, London;
- Non-patent Document 1 Non-patent Document 1
- plastic changes in sexual pain inhibitory system is one of the causes (Clinical Neuroscience, 20, pp.1122- 1125 , 2002) 0
- ginsenoside Rbl which is one of the ginseng fractions, has been shown to be effective in preventing and improving cerebral infarction 'stroke' and spinal cord injury.
- Wen et al. Showed that oral administration of red ginseng powder and intraperitoneal injection of ginseng crude saponin or ginsenoside Rbl for 5 minutes before transient forebrain ischemia for 5 minutes improved learning behavioral disorders and delayed It was reported that the inhibitory effect on nerve cell death was observed (Acta Neuropathol (Berl), 91, pp. 15-22, 1996). Lim et al.
- An object of the present invention is to provide a medicament for treating and / or preventing pain such as neuropathic pain that occurs after peripheral nerve injury or central nerve injury. Means for solving the problem
- the present inventor has conducted intensive studies to solve the above-mentioned problems. As a result, it was found that ginsenoside Rbl can significantly reduce neuropathic pain, and that a medicine containing ginsenoside Rbl as an active ingredient is a peripheral nerve. It has been found to be extremely useful for the treatment and / or prevention of pain such as neuropathic pain that occurs after injury or CNS injury. The present invention has been completed based on the above findings.
- the present invention provides a medicine for treating and / or preventing pain, which contains ginsenoside Rbl as an active ingredient.
- the above-mentioned medicine wherein the pain is chronic pain
- the above-mentioned medicine wherein the pain is neuropathic pain
- the neuropathic pain is caused by peripheral nerve injury and / or central nerve injury.
- a medicament as described above which is pain is provided.
- a medicament for treating and / or preventing pain which comprises ginsenoside Rbl as an active ingredient.
- a 2A adrenergic receptor agonistic drug is provided.
- ginsenoside Rbl for the manufacture of the above-mentioned medicament; and a method for treating and / or preventing pain, comprising treating and / or preventing an effective amount of ginsenoside Rbl.
- a method is provided that comprises administering to a mammal, including a human.
- a method for treating and / or preventing pain comprising administering a therapeutic and / or Z- or prophylactically effective amount of ginsenoside Rbl to mammals including humans.
- Methods are provided for treating and / or preventing pain through the use of drenaline receptors.
- FIG. 1 A graph showing the results for 24 hours after sciatic nerve ligation. The results show that hyperalgesia was significantly alleviated after 3 weeks after ligation by continuous administration of ginsenoside Rbl for 4 weeks. is there.
- FIG. 2 A diagram showing the results in which no recovery of arodiurea was observed even if ginsenoside Rbl was continuously administered for 4 weeks after 24 hours of eyesight after sciatic nerve ligation.
- FIG. 3 The results of examining the effect of ginsenoside Rbl on the suppression of hyperalgesia by administering a serotonin depletion drug (5J-DHT) 3 weeks after sciatic nerve ligation and conducting heat tests before and after administration
- 5J-DHT serotonin depletion drug
- FIG. 4 A heat test was performed 3 weeks after strangulation, and the following day, an adrenergic receptor blocker (puplanolol) was administered. One hour after that, a heat test was performed again, and ginsenoside Rbl was used. It is a figure showing the result of having examined the effect on hyperalgesia suppression.
- FIG. 6 A heat test was performed 3 weeks after strangulation, and the following day, an adrenergic receptor blocker (pentramine) was administered. One hour later, a heat test was performed again, and ginsenoside Rbl was used.
- FIG. 4 is a view showing the results of examining the effect on suppressing hyperalgesia.
- FIG. 2 is a view showing mRNA expression of a 2A phosphorus receptor.
- FIG. 2 is a view showing expression of a 2A phosphorus receptor protein.
- Ginsenoside Rbl is a ginseng saponin, for example, as described in International Publication WO 00/37481, WO 00/48608, WO 01/15717, WO 01/92289, etc. It is known to be useful for the prevention, treatment or treatment of nervous system, and the prevention, treatment or treatment of nerve trauma, and is a substance readily available to those skilled in the art.
- ginsenoside Rbl For ginsenoside Rbl, the screening of substances with similar effects (ginsenoside-like substances) Since the method for screening is known (Japanese patent application, applicant: Masahiro Sanaka, name of invention "Screening method for ginsenoside Rbl-like substance"), the substance screened by the method is used for the efficacy of the medicament of the present invention. It can also be used as a component.
- the term “ginsenoside Rbl” includes the power of natural ginsenoside Rbl ⁇ substances (eg, glycosides) screened by the above method. It should not be interpreted in a limited manner. Further, a substance in the form of a salt, or a substance in the form of a hydrate or solvate can also be used as an active ingredient of the medicament of the present invention.
- the medicament of the present invention is useful for treating and / or preventing pain. Pain is generally described as an unpleasant sensation, emotional experience associated with or expressed by the words of a substantial or potential injury to tissue (International Association for the Study of Pain (IASP) , 1994), physiological pain (acute nociceptive pain), pathological persistent pain (tissue-damaging and inflammatory pain, neuropathic pain), and psychogenic pain.
- IASP International Association for the Study of Pain
- the medicament of the present invention can be applied to any of the above-mentioned pains, chronic pain may be mentioned as a preferable application target, and among them, neuropathic pain may be mentioned as a more preferable target. it can
- Neuropathic pain is intractable pain that results from dysfunction of the peripheral nervous system or central nervous system, and clinically accounts for most of chronic pain.
- the main symptoms are typically “hyperalgesia”, which is an increase in responsiveness to stimuli that are usually painful, and “alody your” (allodynia), which is pain caused by stimuli that do not normally cause pain. ), And “persistent spontaneous pain”.
- the medicament of the present invention can be applied to any of these symptoms, it can be mentioned as “hyperalgesia” and “sustained spontaneous pain”, and can be mentioned as a target of application. Is "hyperalgesia.”
- neuropathic pain there is much resistance to existing painkillers, including nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin and opioid analgesics such as morphine. Treatment and prevention are often difficult.
- NSAIDs nonsteroidal anti-inflammatory drugs
- the medicament of the present invention can exert an excellent analgesic effect even on such neuropathic pain resistant to existing analgesics.
- central nervous system caused by peripheral nerve injury, cerebral infarction or spinal cord injury
- Neuropathic pain that occurs after injury, neuropathic pain caused by cancer, and the like are suitable applications of the medicament of the present invention.
- the types of pain to which the medicament of the present invention is applied are not limited to those specifically described above.
- neuropathic pain models include, but are not limited to, hromc constriction mjury (C and I) moore, Spinal nerve ligation (and hung) moore, and Spared nerve injury models
- Ginsenoside Rbl itself may be administered as the medicament of the present invention, but it is preferably administered as an oral or parenteral pharmaceutical composition that can be produced by a method well known to those skilled in the art.
- the medicament of the present invention can be prepared as a parenteral pharmaceutical composition, and includes, for example, injections, drops, suppositories, inhalants, eye drops, nasal drops, ointments, It can be prepared as a medicament in the form of a transdermal absorption agent, a transmucosal absorption agent, a cream, a patch, or the like, preferably an injection or a drip for intravenous administration.
- compositions suitable for oral administration include, for example, ginsenoside Rb slave substances suitable for oral administration or ginsenoside Rb slave substances prepared as prodrugs, for example, tablets, capsules, powders, fine granules, granules And pharmaceutical preparations in the form of preparations, solutions and syrups.
- the above-mentioned pharmaceutical composition can be produced by adding pharmacologically and pharmaceutically acceptable additives.
- pharmacologically and pharmaceutically acceptable additives include, for example, excipients, disintegrants or disintegration aids, binders, lubricants, coatings, pigments, diluents, bases, dissolution Agents, solubilizing agents, tonicity agents, pH regulators, stabilizers, propellants, adhesives and the like.
- the above-mentioned pharmaceutical composition may contain one or more other medicines such as an analgesic for treating pain.
- ginsenoside Rbl in medicine, see, for example, JP-A-2002-53467, JP-A-2000-191539, and JP-A-2000-302798 and the like, and the drugs described in these patents can be suitably used as the drug of the present invention.
- the dosage of the medicament of the present invention is not particularly limited, and can be appropriately increased or decreased according to various factors that should be usually considered, such as the type of pain, the weight and age of the patient, the condition, and the administration route.
- ginsenoside Rbl as an active ingredient can be used in a weight range of about 0.01 1,000 mg per adult per day.
- the sciatic nerve banding disorder model was created by modifying the neuropathic pain model published by Bennett et al. According to the method of Takeha (Pain, 33, pp.87-107, 1988; Ehime, 21, pp. .192-206, 2002). Under inhalational anesthesia with 3% halothane and laughter, 8-12 week-old Wistar female rats (CLEA Japan, Osaka) were exposed to the bilateral sciatic nerve, and then a 27-gauge needle was placed along the middle of the femur at the mid-femoral level.
- the continuous infusion pump used was an Alzet mini-osmotic pump Model 2004 (DURECT Corporation, Cupertino, USA).
- the right external jugular vein was exposed, and a silicone tube (HELIX MEDICAL, Carpinteria, USA) connected to the pump was inserted into the vein 2.5 cm and fixed. After that, the pump was placed subcutaneously on the back of the rat.
- the silicon tube was used after washing with a saline solution after injecting hen and then left in place.
- ginsenoside Rbl solution (0.10 ⁇ g / ⁇ stomach 0.50 ⁇ g / ⁇ 1) or an equal volume of saline (saline) was added 24 hours after rat sciatic nerve ligation. It was administered intravenously as a shot. Then, using a continuous infusion pump, ginsenoside Rbl at a dose of 12 ⁇ g / day (hereinafter referred to as S12) or 60 ⁇ g / day (hereinafter referred to as S60) (each at 0 ⁇ 25 ⁇ 25) for 4 weeks. was administered intravenously. Similarly, physiological saline was continuously administered intravenously for 4 weeks as a control group.
- S12 12 ⁇ g / day
- S60 60 ⁇ g / day
- PCR was performed using Taq polymerase (Takara, Tokyo) under the following conditions.
- ⁇ -actin
- Annealing was performed at 60 ° C. for 1 minute and extension reaction was performed at 72 ° C. for 1 minute for 30 cycles. ⁇ -actin was used as the internal control.
- the incubation was performed at 10 ° C for 10 minutes, and the supernatant after centrifugation at 15,000 ⁇ m for 10 minutes at 4 ° C was used as a sample.
- the protein was further transferred to a polyvinylidinedilfluoride membrane (Millipore, Bedford, USA) using a transplot apparatus, and an anti-adrenoc-marked tor antibody (ALEXIS BIOCHEMICALS, San Francisco) was used as a primary antibody. Diego, USA)
- Western blotting was performed using an anti-phosphorase 3 rlgG conjugated with alkaline phosphatase (SIGMA Chemicals, St. Louis, USA) as an antibody.
- a heat test was performed 24 hours after sciatic nerve ligation, and only rats with an average latency of both feet of 90% or less of those before surgery were used. Thirty-two animals were randomly divided into three groups (10 to 11 animals in each group) and used for the experiments. A pressure test and a heat test were performed on the third day and 1, 2, 3, 4, 5, and 6 weeks after strangulation. No recovery of arodinia was observed between the Rbl-administered group and the control group. Improvement in hyperalgesia was observed after 3 weeks after force strangulation. Therefore, when Rbl was continuously administered for 24 weeks from 24 hours after strangulation, hyperalgesia was significantly alleviated after 3 weeks after strangulation (FIGS. 1 and 2).
- ⁇ -adrenergic receptor is involved in the hyperalgesia-suppressing effect of ginsenoside Rbl, among ⁇ -adrenergic receptors, ⁇ -adrenergic is considered to be most closely related to analgesia particularly at the spinal cord level. Receptor inheritance in Rbl administration
- neuropathic ⁇ ⁇ which occurs after peripheral nerve injury or central nerve injury.
- C the medicament is provided that has a high efficacy in the treatment and / or prevention of pain, such as in
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/586,454 US20080009469A1 (en) | 2004-01-26 | 2005-01-26 | Medicament for Threapeutic Treating of Pain |
EP05704116A EP1719514A4 (en) | 2004-01-26 | 2005-01-26 | MEDICAMENT FOR TREATING PAIN |
JP2005517314A JP5107521B2 (ja) | 2004-01-26 | 2005-01-26 | 疼痛の治療のための医薬 |
US12/367,976 US20090247461A1 (en) | 2004-01-26 | 2009-02-09 | Methods for therapeutic treatment of pain |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-017024 | 2004-01-26 | ||
JP2004017024 | 2004-01-26 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/367,976 Continuation US20090247461A1 (en) | 2004-01-26 | 2009-02-09 | Methods for therapeutic treatment of pain |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005070437A1 true WO2005070437A1 (ja) | 2005-08-04 |
Family
ID=34805517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/000979 WO2005070437A1 (ja) | 2004-01-26 | 2005-01-26 | 疼痛の治療のための医薬 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20080009469A1 (ja) |
EP (1) | EP1719514A4 (ja) |
JP (1) | JP5107521B2 (ja) |
WO (1) | WO2005070437A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107441105A (zh) * | 2017-08-24 | 2017-12-08 | 浙江大学 | 人参二醇皂苷Rb组分在制备防治疼痛药物中的应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8855759B2 (en) * | 2007-10-09 | 2014-10-07 | The Hong Kong Polytechnic University | Method of treating a rheumatic disorder using combination of transcutaneous electrical nerve stimulation and a ginsenoside |
KR101263451B1 (ko) * | 2011-01-14 | 2013-05-10 | 경희대학교 산학협력단 | 진세노사이드 Rb1 및 Rg3,Compound K,또는 인삼유래 사포닌 추출물을 유효성분으로 함유하는 신경병증성 통증 예방 및 치료용 조성물 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001092289A1 (fr) * | 2000-05-31 | 2001-12-06 | Japan Science And Technology Corporation | Promoteurs de regeneration de tissu cutane contenant le ginsenoside rb1 |
KR100497895B1 (ko) * | 2002-12-05 | 2005-06-29 | 홍림통산(주) | 인삼의 유산균 발효물, 그를 함유하는 인삼 요구르트 및그에 이용되는 유산균 균주 |
-
2005
- 2005-01-26 EP EP05704116A patent/EP1719514A4/en not_active Withdrawn
- 2005-01-26 WO PCT/JP2005/000979 patent/WO2005070437A1/ja active Application Filing
- 2005-01-26 JP JP2005517314A patent/JP5107521B2/ja active Active
- 2005-01-26 US US10/586,454 patent/US20080009469A1/en not_active Abandoned
-
2009
- 2009-02-09 US US12/367,976 patent/US20090247461A1/en not_active Abandoned
Non-Patent Citations (5)
Title |
---|
LEI W. ET AL: "Inhibitory effect of Panex notginseng(arasaponin E1) on the central nervous system", ZHONGCAOYAO, vol. 17, no. 1, 1986, pages 15 - 18, XP008051747 * |
MIN ZHU ET AL: "Biological test on schefflere glycosides and gingseng glycosides by radio-ligand receptor binding assays", vol. 6, 1999, pages 87 - 90, XP002987116 * |
NAH J.J. ET AL: "Effect of ginsenosides, active components of ginseng, on capsaicin-induced pain-related behavior", NEUROPHARMACOLOGY, vol. 39, no. 11, 2000, pages 2180 - 2184, XP002987118 * |
NAH J.J. ET AL: "Effects of spinally administered ginseng total saponin on capsaicin-induced pain and excitatory amino acids-induced nociceptive responses", vol. 23, no. 1, 1999, pages 38 - 43, XP002987119 * |
See also references of EP1719514A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107441105A (zh) * | 2017-08-24 | 2017-12-08 | 浙江大学 | 人参二醇皂苷Rb组分在制备防治疼痛药物中的应用 |
CN107441105B (zh) * | 2017-08-24 | 2021-03-02 | 浙江大学 | 人参二醇皂苷Rb组分在制备防治疼痛药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005070437A1 (ja) | 2007-09-13 |
US20080009469A1 (en) | 2008-01-10 |
JP5107521B2 (ja) | 2012-12-26 |
US20090247461A1 (en) | 2009-10-01 |
EP1719514A1 (en) | 2006-11-08 |
EP1719514A4 (en) | 2007-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI314054B (en) | Novel methods and compositions for alleviating pain | |
Sun et al. | Lappaconitine, a C18-diterpenoid alkaloid, exhibits antihypersensitivity in chronic pain through stimulation of spinal dynorphin A expression | |
Coluzzi et al. | Mechanism-based treatment in chronic neuropathic pain: the role of antidepressants | |
US10695302B2 (en) | Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder | |
JP2018027931A (ja) | 疼痛コントロールのための多剤注入 | |
EP3956025A1 (en) | Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo | |
Gregoretti et al. | Clonidine in perioperative medicine and intensive care unit: more than an anti-hypertensive drug | |
Nesek Adam et al. | Pain management in critically ill patients | |
JP5107521B2 (ja) | 疼痛の治療のための医薬 | |
Visser et al. | Salmon calcitonin in the treatment of post herpetic neuralgia | |
Jung et al. | Isobolographic analysis of drug combinations with intrathecal BRL52537 (κ-opioid agonist), pregabalin (calcium channel modulator), AF 353 (P2X3 receptor antagonist), and A804598 (P2X7 receptor antagonist) in neuropathic rats | |
CN107362351B (zh) | Il-36r的拮抗剂在制备镇痛药物中的应用 | |
US20220288089A1 (en) | Peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response | |
CA3212248A1 (en) | Improved methods of treating diseases resulting from a maladapted stress response | |
Jones et al. | Treatment of pruritus caused by cholestasis with opioid antagonists | |
KR102308146B1 (ko) | 항암제에 의해 유도되는 이질통의 예방 또는 치료용 조성물 및 이를 이용한 치료방법 | |
Raffaeli et al. | Intrathecal drug administration for the treatment of cancer and non-cancer chronic pain | |
JP6551671B2 (ja) | アルツハイマー治療薬 | |
Feng et al. | 2 NMDA Receptor Antagonists, Gabapentinoids, Alpha-2 Agonists, and Dexamethasone | |
Witek et al. | Cushing’s disease: is pasireotide LAR a breakthrough in adjuvant therapy after unsuccessful surgery? | |
Walujo et al. | Opioid-Free Anesthesia (OFA) as a Safe Anesthetic Choice for Epilepsy Patient | |
EP0966286B1 (en) | Attenuation of opioid tolerance by inhibiting inducible nitric oxide synthase pathways in the treatment of pain | |
WO2024091863A1 (en) | Combinatorial, and rotational combinatorial therapies for obesity and other diseases | |
Noe | Daltry Dott | |
Sweeney et al. | Assessment and management of opioid side effects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005517314 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005704116 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005704116 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10586454 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10586454 Country of ref document: US |